Tactics of combined/complex treatment of patients with breast cancer with isolated metastatic lesions of supraclavicular or parasternal lymph nodes
- Authors: Kupriyanov P.1, Zikiryakhodzhaev A.2,1,3, Reshetov I.1, Rasskazova E.4, Khugaeva F.4, Butova Y.4, Duadze I.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
- Research Center of Radiology, Ministry of Health of Russia
- Peoples' Friendship University of Russia
- P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
- Issue: Vol 35, No 2 (2024)
- Pages: 75-78
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/632197
- DOI: https://doi.org/10.29296/25877305-2024-02-14
- ID: 632197
Cite item
Open Access
Access granted
Abstract
Purpose. To evaluate the treatment tactics for patients with breast cancer (BC) with isolated metastatic lesions of the supraclavicular or parasternal lymph nodes (LNs).
Material and methods. We analyzed the data of 134 patients with breast cancer, who were divided into 2 groups: 1st (n=83) – patients with lesions of the supraclavicular and parasternal lymph nodes, both isolated and in combination with lesions of any other groups of lymph nodes; 2nd (n=51) – patients with isolated or combined lesions of only subclavian or axillary lymph nodes. In group 1, lymphadenectomy was performed in 27 patients (subgroup 1A), radiation therapy of the affected lymph nodes was performed in 56 (subgroup 1B). In group 2, patients received chemotherapy for the affected lymph nodes.
Results. Survival after 1 year of observation was almost the same in subgroups 1A (surgical treatment of lymph nodes) and 1B (radiation therapy of lymph nodes) – 96.3 and 96.4%, respectively; after 3 years of observation – 77.8 and 80.4%, respectively; 5-year survival rate – 33.3 and 44.6%, respectively. However, the data obtained were statistically unreliable.
Conclusion. When comparing 5-year overall survival, surgical removal of metastatic supraclavicular and parasternal lymph nodes is inferior to radiation therapy. Thus, it can be assumed that excluding the surgical stage of LN treatment does not worsen the results of therapy in the group of patients with breast cancer and metastatic lesions of supraclavicular or parasternal LNs.
Full Text
About the authors
P. Kupriyanov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0002-5671-6097
Russian Federation, Moscow
A. Zikiryakhodzhaev
Research Center of Radiology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University); Peoples' Friendship University of Russia
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0001-7141-2502
MD
Russian Federation, Moscow; Moscow; MoscowI. Reshetov
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0002-0909-6278
Academician of the Russian Academy of Sciences, MD, Professor
Russian Federation, MoscowE. Rasskazova
P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Author for correspondence.
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0003-0307-8252
Candidate of Medical Sciences
Russian Federation, MoscowF. Khugaeva
P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0001-9749-0445
Russian Federation, Moscow
Yu. Butova
P.A. Herzen Moscow Research Oncology Institute – branch of the National Medical Research Center of Radiology, Ministry of Health of Russia
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0002-0532-8668
Russian Federation, Moscow
I. Duadze
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Email: rasskaz2@yandex.ru
ORCID iD: 0000-0002-9577-584X
Russian Federation, Moscow
References
- Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2022; 239 с. [Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2021 godu. M.: MNIOI im. P.A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2022; 239 р. (in Russ.)]
- Belkacemi Y., Loganadane G., Ghith S. et al. Axillary nodal irradiation practice in the sentinel lymph node biopsy era: Comparison of the contemporary available 3D and IMRT techniques. Br J Radiol. 2020; 93 (1110): 20190351. doi: 10.1259/bjr.20190351
- Berruti A., Amoroso V., Gallo F. et al. Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies. J Clin Oncol. 2014; 32 (34): 3883–91. doi: 10.1200/JCO.2014.55.2836
- Bonotto M., Gerratana L., Poletto E. et al. Measures of outcome in metastatic breast cancer: insights from a realworld scenario. Oncologist. 2014; 19 (6): 608–15. doi: 10.1634/theoncologist.2014-0002
- Borm K.J., Oechsner M., Dusberg M. et al. Irradiation of regional lymph node areas in breast cancer – Dose evaluation according to the Z0011, AMAROS, EORTC 10981-22023 and MA-20 field design. Radiother Oncol. 2020; 142: 195–201. doi: 10.1016/j.radonc.2019.08.021
- Doepker M.P., Zager J.S. Sentinel lymph node mapping in melanoma in the twenty-first century. Surg Oncol Clin N Am. 2015; 24 (2): 249–60. doi: 10.1016/j.soc.2014.12.004
- Fan Y., Xu B., Liao Y. et al. A retrospective study of metachronous and synchronous ipsilateral supraclavicular lymph node metastases in breast cancer patients. Breast. 2010; 19 (5): 365–9. doi: 10.1016/j.breast.2010.03.022
- Gillon P., Touati N., Breton-Callu C. et al. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: An analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017; 79: 226–34. doi: 10.1016/j.ejca.2017.04.012
- Jung J., Kim S.S., Ahn S.D. et al. Treatment Outcome of Breast Cancer with Pathologically Proven Synchronous Ipsilateral Supraclavicular Lymph Node Metastases. J Breast Cancer. 2015; 18 (2): 167–72. doi: 10.4048/jbc.2015.18.2.167
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer Version 4.2022. June 21, 2022.
- Reintgen M., Kerivan L., Reintgen E. et al. Breast lymphatic mapping and sentinel lymph node biopsy: state of the art: 2015. Clin Breast Cancer. 2016; 16 (3): 155–65. doi: 10.1016/j.clbc.2016.02.014
- Shan R., Zhu T., Zhang M. et al. Value of supraclavicular region radiotherapy on patients with pT1-2N1M0 breast cancer after mastectomy. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019; 44 (6): 664–71. doi: 10.11817/j.issn.1672-7347.2019.06.009
- Zhang W., Qi X.M., Chen A.X. et al. The Role of Supraclavicular lymph node dissection in Breast Cancer Patients with Synchronous Ipsilateral Supraclavicular Lymph Node Metastasis. Zhonghua Zhong Liu Za Zhi. 2017; 39 (5): 374–9. doi: 10.3760/cma.j.issn.0253-3766.2017.05.011
- Nikpayam M., Uzan C., Rivera S. et al. Impact of radical surgery on outcome in locally advanced breast cancer patients without metastasis at the time of diagnosis. Anticancer Res. 2015; 35 (3): 1729–34.
- Zhao P., Zou Q., Yuan L. et al. Application of a Three-Dimensional Reconstruction System in Breast Cancer with Ipsilateral Supraclavicular Lymph Node Metastasis: A Case Series. Breast Care (Basel). 2019; 14 (3): 176–9. doi: 10.1159/000492601
- Zhu J., Jiao D., Guo X. et al. Predictive factors and prognostic value of pathologic complete response of ipsilateral supraclavicular lymph nodes in breast cancer after neoadjuvant chemotherapy. Ann Transl Med. 2019; 7 (22): 666. doi: 10.21037/atm.2019.10.22
Supplementary files
